Day: January 18, 2023

Ceridian to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 8th

Written by Customer Service on January 18, 2023. Posted in Public Companies.

TORONTO and MINNEAPOLIS, Jan. 18, 2023 (GLOBE NEWSWIRE) — Ceridian HCM Holding Inc. (NYSE:CDAY) (TSX:CDAY), a global leader in human capital management (HCM) technology, announced today that it will release fourth quarter and full-year 2022 financial results after the close of regular market trading on Wednesday, February 8, 2023. The company will host a live webcast at 5:00 p.m. Eastern Time on February 8, 2023 to discuss the aforementioned financial results. The event can be accessed via direct registration link or through the Ceridian Investor Relations website. A replay and transcript will be available after the conclusion of the live event on the Ceridian Investor Relations website. About Ceridian Ceridian. Makes Work Life Better™. Ceridian is a global human capital management software company. Dayforce, its flagship...

Lamar Advertising Announces Tax Reporting Information For 2022 Distributions on Common Stock

Written by Customer Service on January 18, 2023. Posted in Dividend Reports And Estimates.

BATON ROUGE, La., Jan. 18, 2023 (GLOBE NEWSWIRE) — Lamar Advertising Company (“Lamar”) (Nasdaq: LAMR) today announced certain year-end federal income tax reporting information for its 2022 distributions on its Class A and Class B common stock (“Common Stock”). The following tables summarize, for federal income tax purposes, the nature of distributions paid to holders of Lamar Common Stock, presented on a per share basis, during the calendar year ended December 31, 2022. Stockholders are encouraged to consult with their tax advisors as to the specific tax treatment of Lamar’s 2022 distributions.Lamar Advertising Company Common Stock Ticker Symbol: LAMR Ordinary Qualified Cash Taxable Taxable Sec. 199A Return of Distribution Dividend Dividend Dividend CapitalRecord Date Payable...

Predictive Analytics Market to Touch USD 51.43 Billion by 2028 Thanks to Rising Adoption of Advanced Analytics to Boost Operational Efficiency

Written by Customer Service on January 18, 2023. Posted in Mergers And Acquisitions.

The predictive analytics market value was around USD 13.37 billion in 2021, and it is projected to hit around USD 51.43 billion by 2028, with a CAGR of 14.32% during the forecast period (2022 to 2028). Westford, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) — Numerous opportunities for the predictive analytics market will arise over the forecast period due to the expanding usage of predictive analytics in clinical medicine and medical diagnostics. Predictive analytics is extracting information from current and historical datasets using statistics and modeling approaches to anticipate potential future trends. The market is witnessing traction owing to increased awareness among enterprises regarding the enormous number of data created to predict future outcomes utilizing predictive analytic solutions. In addition, the growth in internet usage...

Meat Snacks Market to reach $ 20.21 Billion by 2028 owing to the emergence of hyperlocal channels will boost the market for meat snacks

Written by Customer Service on January 18, 2023. Posted in Mergers And Acquisitions.

Global Meat Snacks market size was valued at USD 9.88 billion in 2021, and it is expected to reach a value of USD 20.21 billion by 2028, at a CAGR of 7.6% over the forecast period (2022–2028). Westford, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) — SkyQuest’s analysis of the Meat Snacks market provides valuable insights. The industry is currently in a growth phase, with sales increasing at a rate of 7.6% per year. Meat snacks, which serve as twofers to satisfy consumers’ desire for protein-rich as well as dietary options, will see a rise in demand from 2023 to 2028. The recent Paleo diet trend will catalyze the need for high-protein nutrition, which will be heavily influenced by North America. Another amazing aspect to watch for in the meat snacks market will be the increased penetration and exposure of products through newly...

Kosher Food Market to Touch USD 26.21 Billion by 2028 owing to Rising availability on E-Commerce Channel

Written by Customer Service on January 18, 2023. Posted in Mergers And Acquisitions.

Global Kosher Food market size was valued at USD 21.88 billion in 2021, and it is expected to reach a value of USD 26.21 billion by 2028, at a CAGR of 3.6% over the forecast period (2022–2028). Westford, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) — SkyQuest’s analysis of the Kosher Food market provides valuable insights. The industry is currently in a growth phase, with sales increasing at a rate of 3.6% per year. One of the major factors driving the market growth is the rising prevalence of gluten intolerance among the general population. Kosher food is extremely beneficial for people who have celiac disease, as well as dairy and gluten intolerance. Furthermore, the rising demand for kosher packaged foods among non-Jewish consumers is propelling the market growth. Consumers are increasingly favoring ingredient, clean label, and...

OTC Markets Group Announces the 2023 OTCQX Best 50

Written by Customer Service on January 18, 2023. Posted in Public Companies.

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2023 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX Best Market, based on an equal weighting of one-year total return and average daily dollar volume growth. Companies in the 2023 OTCQX Best 50 were ranked based on their performance during the 2022 calendar year. “We congratulate the 2023 OTCQX Best 50 companies on being able to outperform their peers in a year of difficult market conditions,” said Jason Paltrowitz, OTC Markets Group EVP of Corporate Services. “This year’s roster represents the breadth of industries and geographies that contribute to the diverse range of OTCQX-traded...

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

Written by Customer Service on January 18, 2023. Posted in Public Companies.

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI–2620 for Alzheimer’s DiseaseFirst Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trial PI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated Tau Tau accumulation, a key Alzheimer’s disease pathology, correlates with cognitive impairmentLausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease). PI-2620...

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)

Written by Customer Service on January 18, 2023. Posted in Public Companies.

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), resulting in millions of patients gaining access to the broad-spectrum, once daily antibiotic. “The addition of NUZYRA to China’s NRDL means millions of patients now benefit from increased accessibility to this life-saving therapy for serious community-acquired...

VICTORY FILES PERMIT AMENDMENT FOR PRIME DRILL HOLES ON ITS SMOKEY LITHIUM, NEVADA PROPERTY

Written by Customer Service on January 18, 2023. Posted in Public Companies.

Vancouver, Jan. 18, 2023 (GLOBE NEWSWIRE) —As announced on 14 December 2022, Victory’s Exploration Team has completed an on-site geological program to finalize the location of drill holes, building upon its previously reported comprehensive effort to delineate significant lithium mineralization on the Smokey Lithium Property Drill hole locations have been selected to extend strong lithium mineralization intersected previously on the property in hole 09 within the area of interest outlined in detail in the Company’s press release dated 20 October 2022 The Company has now amended and submitted its drill permit application with the newly identified hole locations in this new area of interest contiguous with the southwest part of the original claim blockVANCOUVER, BC, CANADA (18 January 2023) – Victory Battery Metals (CSE:...

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Written by Customer Service on January 18, 2023. Posted in Public Companies.

Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda for the treatment of recurrent glioblastoma (GBM). This Phase 2b multi-center trial is designed to evaluate the safety, tolerability, distribution and efficacy of rhenium (186Re) obisbemeda infused directly into the tumor via convection-enhanced delivery catheters in patients with recurrent GBM progressing after conventional treatment. “In...

Day: January 18, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals